NCT02667236

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 450 (actual)
• Sponsor: Aclaris Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.

Detailed description

This is a randomized, double-blind, vehicle-controlled, parallel group study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face. The Target Lesions will be treated, by an investigational staff member other than the evaluating investigator, a maximum of two times.

Conditions

• Seborrheic Keratosis

Interventions

Type	Name	Description
DRUG	A-101 Solution	Active Drug
OTHER	Vehicle Solution	Placebo

Timeline

• Start date: 2016-01-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2016-01-28
• Last updated: 2018-02-06
• Results posted: 2017-11-13

Locations

1 site across 1 country: United States